This interim analysis of the BIOPSTAGE trial indicates that integrating semiquantitative PSMA PET with mpMRI can improve lesion-level specificity and may allow a more selective biopsy strategy in men with suspected clinically significant prostate cancer. The gene discussed is FOLH1; the disease is prostate cancer.